Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab

Sociedad Española de Neumología y Cirugía Torácica

Status and phase

Completed

Phase 2

Conditions

Severe Asthma

Treatments

Drug: Reslizumab

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03074942

SEP-RES-2016-01

Details and patient eligibility

About

Approximately, 5% of the patients with asthma suffer a difficult-to-control severe variant of the disease. Despite being treated with inhaled corticosteroids (ICs), long-acting β2-agonists (LABA), oral corticosteroids or omalizumab, one or more components of the control concept (symptoms, exacerbations, bronchial obstruction) remain to be resolved. Omalizumab has been proven to safely reduce asthma exacerbations and to decease symptoms and quality of life in severe allergic asthmatics. However, approximately 25% of the treated patients fail to respond to this monoclonal antibody. The rest of them show different degrees of response, although the rate of asthmatics who achieve control of the disease is unknown because clinical trials of omalizumab have been carried out to assess the impact of the drug on exacerbations, symptoms or even pulmonary function, but its effect on control was not evaluated. Therefore, there is a need to find new therapeutic options for those severe asthmatics who remain uncontrolled despite having received all the recommended therapies (including omalizumab). Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) that has been recently found to reduce exacerbations and to improve pulmonary function and symptoms in patients with severe asthma and high peripheral eosinophil counts. It would be important to demonstrate that Reslizumab is able to improve the clinical condition of severe asthma patients with no therapeutic options.

Enrollment

30 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients between 18 and 70 years of age,
Patients diagnosed with severe uncontrolled asthma
Patients who give informed consent.
Previous treatment with omalizumab that was discontinued because lack of efficacy (symptoms -ACT <20, exacerbations) or adverse effects.
Patients with a high blood eosinophil count (400 μl) at least once in the previous 3 years.
Women should be surgically sterilized, at least 2 years have passed since menopause, or must have a negative pregnancy test within 7 days prior to initiation of treatment.
Women of childbearing potential (not surgically sterilized or menopausal for less than 2 years) should use a medically accepted method of contraception and should agree to continue using this method during the study and at least 30 days after the end of the study.
Patient should be willing and able to comply with the study restrictions and attend the visits indicated in the protocol to carry out the follow-up evaluations detailed in the protocol.

Exclusion criteria

Diagnosis of asthma-COPD (Chronic Obstructive Pulmonary Disease) overlap syndrome.
Active and former smokers of>10 packages / year.
Exacerbations during the previous 4 weeks.
Current treatment with omalizumab or last dose of omalizumab in the 5 months prior to inclusion of the patient in the study. 5- Exposure to another monoclonal antibody.
Participation in another clinical trial.
Uncontrolled clinically significant disease, which may interfere with study procedures, interpretation of efficacy results, or compromise patient safety.
Underlying lung disorder.
Known hypereosinophilic syndrome.
A pregnant or lactating woman, or who intends to become pregnant during the study.
Participation in a clinical trial within 30 days prior to the start of treatment.
Previous exposure to reslizumab or other anti-IL-5 monoclonal antibody.
Immunodeficiency disorder, including HIV.
Suspected drug or alcohol abuse.
Active helminth parasite infection or for which treatment was received in the 6 months prior to the start of treatment.
History of allergic reaction or hypersensitivity to any component of the study drug.